MedTrace Logo

Maternal Determinants of Immunity to Influenza

NCT06716567 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2025-03-24

No results posted yet for this study

Summary

The overall objective of the project is to determine the impact of pregnancy on the response to influenza immunization.

Conditions

  • Vaccination; Infection
  • Maternal-Fetal Relations
  • Influenza
  • Immunoglobulins

Interventions

BIOLOGICAL

Influenza vaccine

Alpharix-Tetra®, Vaxigrip Tetra® and Influvac Tetra® were used as influenza vaccines in the 2020-2021, 2021-2022, and 2022-2023 seasons respectively.

Sponsors & Collaborators

  • Institute for Medical Immunology, Université libre de Bruxelles

    collaborator UNKNOWN

  • Centre Hospitalier Universitaire Saint Pierre

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-16
Primary Completion
2023-11-10
Completion
2023-11-10

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06716567 on ClinicalTrials.gov